A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Acronyms DEVELOP
- Sponsors Janssen Biotech
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 Planned primary completion date changed from 31 Dec 2038 to 30 Jun 2038.
- 13 Jun 2017 Planned End Date changed from 22 Jun 2039 to 30 Jun 2038.